Review of once-monthly oral ibandronate and the use thereof

T De Villiers; M Davey; B Cassim; W De Lange

Review of once-monthly oral ibandronate and the use thereof

T De Villiers
M Davey
B Cassim
W De Lange

Keywords: oral ibandronate

Abstract

An advisory board meeting of key opinion leaders was held in 2015 to discuss the clinical data on oral ibandronate in the treatment of postmenopausal osteoporosis. Boniva 150 mg (ibandronate) oral once-monthly is indicated for the treatment of osteoporosis in postmenopausal women, in order to reduce the risk of vertebral fractures.¹

Author Biographies

T De Villiers

Chairman Ibandronate Oral Advisory Group

M Davey

Ibandronate Oral Advisory Group

B Cassim

Ibandronate Oral Advisory Group

W De Lange

Ibandronate Oral Advisory Group

Issue

Vol 59 No 4: July/August 2017

Section

Review Articles

By submitting manuscripts to SAFP, authors of original articles are assigning copyright to the South African Academy of Family Physicians. Copyright of review articles are assigned to the Publisher, Medpharm Publications (Pty) Ltd, unless otherwise specified. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAFP for educational and research purposes without obtaining permission.